Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Veeva Acquires Physicians World

Veeva Systems has acquired Physicians World, a leading provider of speakers bureau services.

Read More »

W2O Acquires to Broaden International Reach of its Scientific & Medical Marketing Communications Solutions

W2O announced the acquisition of, continuing the company’s global expansion in scientific and medical marketing communications.

Read More »

Takeda to sell portfolio of select drugs for $660 million

Takeda Pharmaceutical Co. Ltd. will sell some over-the-counter and prescription drugs to Germany’s Stada Arzneimittel AG for a total value of $660 million.

Read More »

EVERSANA to acquire Cornerstone Research Group

EVERSANA, a leading independent provider of commercial services to the life science industry, announced an agreement to acquire Canada-based Cornerstone Research Group Inc.

Read More »

Alexion fortifies rare blood disorder drugs business

Alexion Pharmaceuticals Inc. agreed to buy smaller biotech company Achillion Pharmaceuticals Inc. in a deal initially valued at $930 million.

Read More »

Belgium’s UCB to buy Ra Pharmaceuticals

UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.

Read More »

W2O Acquires Arcus Medica to Accelerate and Deepen Scientific and Medical Communications Offering

W2O – a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector – acquired Arcus Medica, a recognized leader in medical and scientific communications.

Read More »

Sweden’s Sobi to Acquire Dova Pharmaceuticals

Shares of Dova Pharmaceuticals were up more than 38 percent after Sweden-based Sobi announced the intended acquisition of the North Carolina-based company for $915 million.

Read More »

Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

Clovis Oncology Inc. entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH, a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.

Read More »

Lundbeck buys Alder for $2 billion, eyes ‘blockbuster’ migraine therapy

Denmark’s Lundbeck agreed to buy Alder BioPharmaceuticals in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom